Category Archives: Kidney-disease-drug-development

A Renaissance in Chronic Kidney Disease Treatment Is Underway

From: LABiotech.eu BY JONATHAN SMITH Chronic kidney disease is an incurable condition where the kidneys are damaged over time and gradually stop working properly. It usually overlaps with common age-related conditions such as cardiovascular disease and diabetes. In spite of a growing market, … Continue reading

Posted in M Loghman-Adham, MD | Leave a comment

Akebia Therapeutics Announces Approval of Vadadustat in Japan for the Treatment of Anemia Due to Chronic Kidney Disease in Dialysis-Dependent and Non-Dialysis Dependent Adult Patients

June 29, 2020 at 7:41 AM EDT First Regulatory Approval for Akebia’s HIF-PHI Marks Beginning of Next Phase of Akebia’s Growth Story CAMBRIDGE, Mass., June 29, 2020 /PRNewswire/ — Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the … Continue reading

Posted in M Loghman-Adham, MD | Leave a comment

Positive Top-Line Results from Global Phase 3 Program of Vadadustat for Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis

CAMBRIDGE, Mass., May 5, 2020 /PRNewswire/ — Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced positive top-line results from INNO2VATE, the first of its two global Phase 3 cardiovascular … Continue reading

Posted in M Loghman-Adham, MD | Leave a comment

A proposed clinical trial for COVID-19 pneumonia

This article was originally published on March 23, 2020 on LinkedIn (see link here): Anecdotal reports suggest that chloroquine (CQ), an old antimalaria drug and its less toxic derivative, hydroxychloroquine (HCQ), may be effective as antiviral treatments against the novel … Continue reading

Posted in M Loghman-Adham, MD | Leave a comment

Dapagliflozin–saxagliptin ‘attractive’ options for patients with type 2 diabetes with chronic kidney disease

MedwireNews (April 16, 2019): Dapagliflozin, with or without saxagliptin, reduces albuminuria in people with type 2 diabetes and moderate-to-severe chronic kidney disease when used in combination with antihypertensive treatments, DELIGHT study data show. Furthermore, using the sodium-glucose co-transporter (SGLT)2 inhibitor … Continue reading

Posted in M Loghman-Adham, MD | Leave a comment

Proton pump inhibitors linked to increased risk of renal toxicity

February 19, 2019 | By Heather Buschman, PhD Source:  UC San Diego News Center Proton pump inhibitors (PPIs), which include well-known brand names Prilosec, Nexium and Prevacid, are among the most commonly prescribed medications in the world. Approximately 10 percent of adults in … Continue reading

Posted in M Loghman-Adham, MD | Leave a comment

Disappointing Data From Phase 3 STELLAR-4 Study of Selonsertib in Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)

FOSTER CITY, Calif.–(BUSINESS WIRE)–Feb. 11, 2019– Gilead Sciences, Inc. (Nasdaq: GILD) today announced that STELLAR-4, a Phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of selonsertib, an investigational, once-daily, oral inhibitor of apoptosis signal-regulating kinase 1 (ASK1), in patients … Continue reading

Posted in M Loghman-Adham, MD | Leave a comment

Alexion Announces Positive Top-Line Results From Phase 3 Study Of ULTOMIRIS™ (Ravulizumab-Cwvz) In Complement Inhibitor-Naïve Patients With Atypical Hemolytic Uremic Syndrome (AHUS)

Monday, January 28, 2019 6:30 am EST BOSTON–(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the Phase 3 study of ULTOMIRIS™ (ravulizumab-cwvz), the company’s long-acting C5 complement inhibitor, met its primary objective in complement inhibitor-naïve patients with atypical hemolytic uremic syndrome … Continue reading

Posted in M Loghman-Adham, MD | Leave a comment

Tricida Announces Positive Pivotal Phase 3 Clinical Trial Results for TRC101 in CKD Patients With Metabolic Acidosis

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Tricida, Inc., a late-stage pharmaceutical company, announced results from its pivotal Phase 3 double-blind, randomized, placebo-controlled, multi-center Phase 3 clinical trial, TRCA-301, in 217 chronic kidney disease (CKD) patients with metabolic acidosis. TRC101 represents a first-in-class candidate … Continue reading

Posted in M Loghman-Adham, MD | Leave a comment

AstraZeneca Reports Full Results from DECLARE-TIMI 58 Cardiovascular Outcomes Trial for FARXIGA (dapagliflozin)

November 12, 2018;  Reproduced from StreetInsider AstraZeneca today announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for FARXIGA (dapagliflozin). The data were presented as a late-breaking abstract (#19485) at the American Heart Association (AHA) Scientific Sessions … Continue reading

Posted in M Loghman-Adham, MD | Leave a comment